AMBIGUOUS RESULTS

Beurer's heat device cut mosquito-bite itch nearly in half in small trial

A 22-person German registry trial and a 1,750-person published study both tie concentrated heat applied to the bite site to faster itch relief than no treatment, with no drug involved.

By AppliedXLJuly 8, 2026Trial DRKS00033004

Executive Summary

A controlled trial of Beurer's handheld heat device for insect bites reported faster and larger itch reduction than no treatment, with no adverse events.
A separately published, far larger study of the same heat-based approach reported a similar direction of effect, reinforcing the mechanism rather than the device itself.
The controlled trial's sample size is small, and the sponsor's own framing of the finding as decisive drew a spin flag, so the effect size should be read as preliminary rather than confirmed.
Insect-bite itch has no heat-based device competitor in active testing, leaving this result without a direct comparator to benchmark against.

The trial

The Institut Prof. Kurscheid-run trial, registered with the German Clinical Trials Register as DRKS00033004, enrolled 22 participants who were bitten by two mosquito species under laboratory conditions. Itch scores at roughly two minutes after treatment measured 2.40 on a 10-point scale for the device versus 4.30 for untreated bites. Over the full 60-minute observation window, treated bites produced a cumulative itch exposure score of 97 versus 161 for untreated bites, a difference the trial reported as statistically significant at p<0.01 across 44 total observations. No adverse events were reported in the trial. [DRKS00033004, DOC-1]

How it was done

The design paired a device-treated bite against an untreated control bite on the same or comparable participants under controlled laboratory exposure to two mosquito species, rather than a placebo-device arm. Beurer's press release also cited a separate published study in Acta Dermato-Venereologica, run by researchers at Charite Universitatsmedizin Berlin and the Fraunhofer Institute, that tracked more than 12,000 heat treatments across 1,750 participants and reported itch reductions of 57% at one minute and 81% at five to ten minutes, with side effects documented in under 0.13% of more than 48,000 data points. Both studies attribute the effect to heat activating TRPV1 nerve receptors, a mechanism the release describes as counter-stimulation that suppresses itch signaling before it registers as discomfort. Studies

The spin flag

Beurer's president of North America, Britta Dittrich, said the evidence is compelling "not just the size of the effect, but its consistency across two independent studies, two research methodologies, two mosquito species, and a broad cross-section of the general population". That framing, paired with the small size of the registered trial, drew a sponsor-spin flag: a company-commissioned 22-person trial promoted through a consumer press release is a different evidentiary bar than an independent, adequately powered replication. Studies

The competitive field

No trial in the broader insect-bite-itch and pruritus landscape shares the device's heat-based mechanism; the closest active programs are Sanofi's Phase 3 dupilumab trials for lichen simplex chronicus, an IL-4 receptor antagonist for a distinct chronic itch condition rather than acute insect-bite response, and a hyaluronic acid trial for general skin pruritus. That leaves the BR60 without a direct comparator on mechanism, meaning any future disclosure would need to be judged against its own two studies rather than against a rival device or drug readout.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.